Clinical trials are currently underway using a fully human IgG1κ monoclonal antibody that recognizes domain 2 of human and rodent CTGF (this monoclonal is called FG-3019 and was developed by Fibrogen, Inc., South San Francisco, CA) as a novel therapy to treat patients with Pancreatic cancer, idiopathic pulmonary fibrosis, and liver fibrosis due to chronic hepatitis B infection [71]. Here, CCN2 is linked to Hepatic fibrosis.